These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

880 related articles for article (PubMed ID: 14518724)

  • 41. Characterization of hypervariable region in hepatitis C virus envelope protein during acute and chronic infection.
    Higashi K; Tsukiyama-Kohara K; Tanaka T; Tanaka E; Kiyosawa K; Kohara M
    Arch Virol; 2005 May; 150(5):883-98. PubMed ID: 15662481
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients.
    Missale G; Cariani E; Lamonaca V; Ravaggi A; Rossini A; Bertoni R; Houghton M; Matsuura Y; Miyamura T; Fiaccadori F; Ferrari C
    Hepatology; 1997 Sep; 26(3):792-7. PubMed ID: 9303515
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Internal processing of hepatitis C virus NS3 protein.
    Shoji I; Suzuki T; Sato M; Aizaki H; Chiba T; Matsuura Y; Miyamura T
    Virology; 1999 Feb; 254(2):315-23. PubMed ID: 9986797
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Use of DNA sequence hybridization with specific oligonucleotide probes to identify hepatitis C virus genotypes].
    Domingo MJ; Fernández I; Lumbreras C; Manzanares J; Morales JM; Noriega AR; Fuertes A
    Enferm Infecc Microbiol Clin; 1996; 14(7):433-5. PubMed ID: 8991438
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatitis C in human immunodeficiency virus-coinfected patients: increased variability in the hypervariable envelope coding domain.
    Sherman KE; Andreatta C; O'Brien J; Gutierrez A; Harris R
    Hepatology; 1996 Apr; 23(4):688-94. PubMed ID: 8666318
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.
    Saito T; Ito T; Ishiko H; Yonaha M; Morikawa K; Miyokawa A; Mitamura K
    Am J Gastroenterol; 2003 Jun; 98(6):1377-83. PubMed ID: 12818284
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy.
    Vicenti I; Rosi A; Saladini F; Meini G; Pippi F; Rossetti B; Sidella L; Di Giambenedetto S; Almi P; De Luca A; Caudai C; Zazzi M
    J Antimicrob Chemother; 2012 Apr; 67(4):984-7. PubMed ID: 22258932
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diversity of 1,213 hepatitis C virus NS3 protease sequences from a clinical virology laboratory database in Marseille university hospitals, southeastern France.
    Hajji H; Aherfi S; Motte A; Ravaux I; Mokhtari S; Ruiz JM; Poizot-Martin I; Tourres C; Tivoli N; Gérolami R; Tamalet C; Colson P
    J Med Virol; 2015 Nov; 87(11):1921-33. PubMed ID: 25959702
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatitis C virus recombinants are rare even among intravenous drug users.
    Viazov S; Ross SS; Kyuregyan KK; Timm J; Neumann-Haefelin C; Isaeva OV; Popova OE; Dmitriev PN; El Sharkawi F; Thimme R; Michailov MI; Roggendorf M
    J Med Virol; 2010 Feb; 82(2):232-8. PubMed ID: 20029799
    [TBL] [Abstract][Full Text] [Related]  

  • 51. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5.
    Vallet S; Viron F; Henquell C; Le Guillou-Guillemette H; Lagathu G; Abravanel F; Trimoulet P; Soussan P; Schvoerer E; Rosenberg A; Gouriou S; Colson P; Izopet J; Payan C;
    Antivir Ther; 2011; 16(7):1093-102. PubMed ID: 22024525
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of naturally occurring active site mutations on hepatitis C virus NS3 protease specificity.
    Beyer BM; Zhang R; Hong Z; Madison V; Malcolm BA
    Proteins; 2001 May; 43(2):82-8. PubMed ID: 11276078
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.
    Suzuki F; Suzuki Y; Akuta N; Sezaki H; Yatsuji H; Arase Y; Hirakawa M; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Iwasaki S; Kumada H
    J Clin Virol; 2010 Jan; 47(1):76-8. PubMed ID: 19857995
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates.
    Qi X; Bae A; Liu S; Yang H; Sun SC; Harris J; Delaney W; Miller M; Mo H
    Antiviral Res; 2009 Feb; 81(2):166-73. PubMed ID: 19063924
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genetic variations in a well conserved 5'-untranslated region of hepatitis C virus genome isolated in Pakistan.
    Yasmeen A; Siddiqui AA; Hamid S; Sultana T; Jafri W; Persson MA
    J Virol Methods; 2009 Sep; 160(1-2):38-47. PubMed ID: 19406160
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inferred hepatitis C virus quasispecies diversity is influenced by choice of DNA polymerase in reverse transcriptase-polymerase chain reactions.
    Mullan B; Kenny-Walsh E; Collins JK; Shanahan F; Fanning LJ
    Anal Biochem; 2001 Feb; 289(2):137-46. PubMed ID: 11161307
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The RNA aptamer-binding site of hepatitis C virus NS3 protease.
    Hwang J; Fauzi H; Fukuda K; Sekiya S; Kakiuchi N; Shimotohno K; Taira K; Kusakabe I; Nishikawa S
    Biochem Biophys Res Commun; 2000 Dec; 279(2):557-62. PubMed ID: 11118325
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular cloning, sequencing and expression of core and NS3 fragments of HCV from patients with HCV infection.
    Tan DM; Hu GL; Arima T; Zhang Z; Nanba T; Hatanaka T
    Chin Med J (Engl); 1993 Jul; 106(7):522-6. PubMed ID: 8243124
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genetic heterogeneity and molecular epidemiology of GB virus C/hepatitis G virus in China.
    An P; Luo H; Lu T; O'Brien SJ; Winkler C
    J Hum Virol; 2000; 3(6):299-305. PubMed ID: 11100910
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genotyping and resistance profile of hepatitis C (HCV) genotypes 1-6 by sequencing the NS3 protease region using a single optimized sensitive method.
    Besse B; Coste-Burel M; Bourgeois N; Feray C; Imbert-Marcille BM; André-Garnier E
    J Virol Methods; 2012 Oct; 185(1):94-100. PubMed ID: 22728274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.